Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response von Goetz, M P, Kamal, A, Ames, M M

Volltext

The Hsp90 chaperone complex as a novel target for cancer therapy von Goetz, M. P., Toft, D. O., Ames, M. M., Erlichman, C.

Volltext

CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies von Goetz, M P, Ingle, J N

Volltext

Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression o... von Damodaran, S., O’Sullivan, C.C., Elkhanany, A., Anderson, I.C., Barve, M., Blau, S., Cherian, M.A., Peguero, J.A., Goetz, M.P., Plourde, P.V., Portman, D.J., Moore, H.C.F.

Volltext

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3 von Goetz, M.P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I.H., Campone, M., Chen, S.-C., Manso, L.M., Paluch-Shimon, S., Freedman, O.C., O’Shaughnessy, J., Pivot, X., Tolaney, S.M., Hurvitz, S.A., Llombart-Cussac, A., André, V., Saha, A., van Hal, G., Shahir, A., Iwata, H., Johnston, S.R.D.

Volltext

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm von Haddox, C.L., Shenoy, N., Shah, K.K., Kao, J.C., Jain, S., Halfdanarson, T.R., Wijdicks, E.F., Goetz, M.P.

Volltext

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations von Province, M A, Goetz, M P, Brauch, H, Flockhart, D A, Hebert, J M, Whaley, R, Suman, V J, Schroth, W, Winter, S, Zembutsu, H, Mushiroda, T, Newman, W G, Lee, M-T M, Ambrosone, C B, Beckmann, M W, Choi, J-Y, Dieudonné, A-S, Fasching, P A, Ferraldeschi, R, Gong, L, Haschke-Becher, E, Howell, A, Jordan, L B, Hamann, U, Kiyotani, K, Krippl, P, Lambrechts, D, Latif, A, Langsenlehner, U, Lorizio, W, Neven, P, Nguyen, A T, Park, B-W, Purdie, C A, Quinlan, P, Renner, W, Schmidt, M, Schwab, M, Shin, J-G, Stingl, J C, Wegman, P, Wingren, S, Wu, A H B, Ziv, E, Zirpoli, G, Thompson, A M, Jordan, V C, Nakamura, Y, Altman, R B, Ames, M M, Weinshilboum, R M, Eichelbaum, M, Ingle, J N, Klein, T E

Volltext

Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial von Goetz, M.P., Bagegni, N.A., Batist, G., Brufsky, A., Cristofanilli, M.A., Damodaran, S., Daniel, B.R., Fleming, G.F., Gradishar, W.J., Graff, S.L., Grosse Perdekamp, M.T., Hamilton, E., Lavasani, S., Moreno-Aspitia, A., O’Connor, T., Pluard, T.J., Rugo, H.S., Sammons, S.L., Schwartzberg, L.S., Stover, D.G., Vidal, G.A., Wang, G., Warner, E., Yerushalmi, R., Plourde, P.V., Portman, D.J., Gal-Yam, E.N.

Volltext

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance) von Yoon, H.H., Foster, N.R., Meyers, J.P., Steen, P.D., Visscher, D.W., Pillai, R., Prow, D.M., Reynolds, C.M., Marchello, B.T., Mowat, R.B., Mattar, B.I., Erlichman, C., Goetz, M.P.

Volltext

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer von Veeraraghavan, J., De Angelis, C., Mao, R., Wang, T., Herrera, S., Pavlick, A.C., Contreras, A., Nuciforo, P., Mayer, I.A., Forero, A., Nanda, R., Goetz, M.P., Chang, J.C., Wolff, A.C., Krop, I.E., Fuqua, S.A.W., Prat, A., Hilsenbeck, S.G., Weigelt, B., Reis-Filho, J.S., Gutierrez, C., Osborne, C.K., Rimawi, M.F., Schiff, R.

Volltext

Corrigendum to “Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria”: [Annals of Oncology 32 (2021) 950-953]... von Gao, J.J., Krol, D., Narayan, P., Cardoso, F., Regan, M.M., Goetz, M.P., Hurvitz, S.A., Mauro, L., Hodgdon, C., Miller, C.P., Booth, B., Bloomquist, E., Ison, G., Osgood, C., Bhatnagar, V., Fashoyin-Aje, L., Pazdur, R., Amiri-Kordestani, L., Beaver, J.A.

Volltext

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria von Gao, J.J., Krol, D., Narayan, P., Cardoso, F., Regan, M.M., Goetz, M.P., Hurvitz, S.A., Mauro, L., Hodgdon, C., Miller, C.P., Booth, B., Bloomquist, E., Ison, G., Osgood, C., Bhatnagar, V., Fashoyin-Aje, L., Pazdur, R., Amiri-Kordestani, L., Beaver, J.A.

Volltext

Characterization of Dislocations in (112)B HgCdTe/CdTe/Si von Benson, J. D., Bubulac, L. O., Smith, P. J., Jacobs, R. N., Markunas, J. K., Jaime-Vasquez, M., Almeida, L. A., Stoltz, A. J., Wijewarnasuriya, P. S., Brill, G., Chen, Y., Lee, U., Vilela, M. F., Peterson, J., Johnson, S. M., Lofgreen, D. D., Rhiger, D., Patten, E. A., Goetz, P. M.

Volltext

Dislocation Analysis in (112)B HgCdTe/CdTe/Si von Benson, J. D., Farrell, S., Brill, G., Chen, Y., Wijewarnasuriya, P. S., Bubulac, L. O., Smith, P. J., Jacobs, R. N., Markunas, J. K., Jaime-Vasquez, M., Almeida, L. A., Stoltz, A., Lee, U., Vilela, M. F., Peterson, J., Johnson, S. M., Lofgreen, D. D., Rhiger, D., Patten, E. A., Goetz, P. M.

Volltext

HgCdTe focal plane arrays for dual-color mid- and long-wavelength infrared detection von SMITH, E. P. G, PHAM, L. T, COUSSA, R. A, KOSAI, K, RADFORD, W. A, GIEGERICH, L. M, EDWARDS, J. M, JOHNSON, S. M, BAUR, S. T, ROTH, J. A, NOSHO, B, DE LYON, T. J, VENZOR, G. M, JENSEN, J. E, LONGSHORE, R. E, NORTON, E. M, NEWTON, M. D, GOETZ, P. M, RANDALL, V. K, GALLAGHER, A. M, PIERCE, G. K, PATTEN, E. A

Volltext

Fabrication and characterization of two-color midwavelength/long wavelength HgCdTe infrared detectors von SMITH, E. P. G, PATTEN, E. A, JOHNSON, S. M, RADFORD, W. A, GOETZ, P. M, VENZOR, G. M, ROTH, J. A, NOSHO, B. Z, BENSON, J. D, STOLTZ, A. J, VARESI, J. B, JENSEN, J. E

Volltext

Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials von Rugo, H.S., Tolaney, S.M., Huober, J., Toi, M., André, V., Barriga, S., Forrester, T., Sledge, G.W., Goetz, M.P.

Volltext

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after i... von Loibl, S., Metzger, O., Mandrekar, S.J., Mundhenke, C., Seiler, S., Valagussa, P., DeMichele, A., Lim, E., Tripathy, D., Winer, E.P., Huang, C., Carey, L., Francis, P., Miller, K.D., Goetz, M.P., Prat, A., Loi, S., Krop, I., Gianni, L., Ciruelos, E.M.

Volltext

Response to letters to the Editor on ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results o... von Goetz, M.P., André, V., Johnston, S.R.D.

Volltext

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study von Harbeck, N., Rastogi, P., Martin, M., Tolaney, S.M., Shao, Z.M., Fasching, P.A., Huang, C.S., Jaliffe, G.G., Tryakin, A., Goetz, M.P., Rugo, H.S., Senkus, E., Testa, L., Andersson, M., Tamura, K., Del Mastro, L., Steger, G.G., Kreipe, H., Hegg, R., Sohn, J., Guarneri, V., Cortés, J., Hamilton, E., André, V., Wei, R., Barriga, S., Sherwood, S., Forrester, T., Munoz, M., Shahir, A., San Antonio, B., Nabinger, S.C., Toi, M., Johnston, S.R.D., O’Shaughnessy, J., Jimenez, M.M., Johnston, S., Boyle, F., Steger, G.G., Neven, P., Jiang, Z., Campone, M., Huober, J., Shimizu, C., Cicin, I., Wardley, A., Tolaney, S.M., Abuin, G.G., Zarba, J., Lim, E., Sant, P., Liao, N., Christiansen, B., Eigeliene, N., Martin-Babau, J., Ettl, J., Mavroudis, D., Chiu, J., Boer, K., Nagarkar, R., Paluch-Shimon, S., Moscetti, L., Sagara, Y., Kim, S.-B., Maciel, M.M., Tjan-Heijnen, V., Broom, R., Lacko, A., Schenker, M., Volkov, N., Sim Yap, Y., Coccia-Portugal, M., Ángel García Sáenz, J., Andersson, A., Chao, T.-Y., Gokmen, E., Harputluoglu, H., Berzoy, O., Patt, D., McArthur, H., Chew, H., Chalasani, P., Kaufman, P., Tedesco, K., Graff, S.L.

Volltext